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2,2’-Bipyridine-Modified Tamoxifen: A Versatile Vector for
Molybdacarboranes
Benedikt Schwarze,[a] Sanja Jelača,[b] Linda Welcke,[a] Danijela Maksimović-Ivanić,[b]
Sanja Mijatović,[b] and Evamarie Hey-Hawkins*[a]
Investigations on the antitumor activity of metallacarboranes
are sparse in the literature and limited to a handful of ruthena-
and molybdacarboranes. In this study, the molybdacarborane
fragment [3-(CO)2-closo-3,1,2-MoC2B9H11] was combined with a
vector molecule, inspired by the well-known drug tamoxifen or
4,4’-dihydroxytamoxifen (TAM-diOH). The molybdacarborane
derivative [3,3-{4-[1,1-bis(4-hydroxyphenyl)but-1-en-2-yl]-2,2‘-bi-
pyridine-k2N,N’}-3-(CO)2-closo-3,1,2-MoC2B9H11] (10), as well as
the ligand itself 4-[1,1-bis(4-hydroxyphenyl)but-1-en-2-yl]-2,2‘-
bipyridine (6) showed cytotoxic activities in the low micromolar
range against breast adenocarcinoma (MDA-MB-231, MDA-MB-
361 and MCF-7), human glioblastoma (LN-229) and human
glioma (U-251) cell lines. In addition, compounds 6 and 10 were
found to induce senescence and cytodestructive autophagy,
lower ROS/RNS levels, but only the molybdacarborane 10
induced a strong increase of nitric oxide (NO) concentration in
the MCF-7 cells.
Introduction
Medicinal chemistry is still dominated by purely organic molecules,
but bioinorganic chemistry is becoming more and more important
and several successful examples of metal-based drugs have
already been reported (see special issue on Metals in Medicine in
ACS Chemical Reviews).[1] However, the available biological data
for molybdenum(II) complexes of the type [Mo(R)(L)X] (where R=
(η3-C3H5)
  , (η5-C5H5)
  , (η5-C9H7)
  ; L=1,10-phenanthroline, 2,2’-
bipyridine, (CO)2, (MeCN)2; X=Cl
  , BF4
  ) are very limited, and only
a few studies were reported until now.[2] On the other hand,
commercially available boron-based drugs are still rare, and mainly
employed in boron neutron capture therapy (BNCT).[3] Unlike
hydrocarbons, boranes and carboranes readily form clusters in a
large variety of 3D geometric shapes. The icosahedral closo-
dicarbadodecaboranes or carboranes are highly interesting, due to
their hydrophobicity, which is beneficial for transport across the
blood-brain barrier (BBB), their inorganic nature preventing
enzymatic degradation, their inherent low toxicity lowering side
effects, their high boron content for BNCT, the variety of possible
substitution patterns employing the three isomers (ortho-, meta-,
para-carborane) and their 3D aromatic structures can be employed
as bulky phenyl or cyclopentadienyl analogues.[4] Thus, a deboro-
nation (i.e. formal loss of a B+ unit) of the closo-C2B10H12 cluster
and deprotonation, the so-called dicarbollide, [C2B9H11]
2  , is
obtained and can be employed in the preparation of a large
variety of transition metal complexes resulting in full-, mixed- or
half-sandwich structures.[5] Potential applications of the full-
sandwich cobalt bis(dicarbollide) ([3,3’-Co(1,2-C2B9H11)2]
  , COSAN)
derivatives in medicine are well investigated,[6,7] but not as a
pharmacophore. Also cytotoxic/cytostatic icosahedral mixed-sand-
wich metallacarboranes, e.g. [3-(η6-arene)-3,1,2-RuC2B9H11], have
been reported.[8,9] Other half- and mixed-sandwich complexes with
potential application in medicine have been summarized in the
literature.[4] One advantage of half-sandwich metallacarboranes is
the incorporation of biologically relevant ligands in the coordina-
tion sphere of the metals, as in the present study, where [3-(2,2’-
bipyridine-k2N,N’)-3-(CO)2-closo-3,1,2-MoC2B9H11] (i) was equipped
with a vector molecule which was inspired by the well-known
tamoxifen. Further examples were reported by Causey et al.,[10]
Hawkins et al.,[11] Pruitt et al.[12] and Louie et al.[13] who used stable
and hydrophobic rhenacarboranes including the [Re(L)(CO)2] frag-
ment (L=2,2’-bipyridine derivative or [NO]+) as imaging agents.
Nuclear receptor ligands using highly hydrophobic icosahe-
dral carborane clusters in structures like estradiol,[14]
testosterone[15] or selective estrogen receptor modulators
(SERMs)[16] were already reported. Also, a carborane-containing
tamoxifen derivative, namely boroxifen, was synthesized, which
showed, however, limited benefits.[17] Employing tamoxifen as
lead structure is promising, because it exhibits estrogenic/
antiestrogenic activity as well as cytotoxic properties,[18] and is
also active in prevention of osteoporosis in postmenopausal
women with early-stage breast cancer[19] and in the protection
of cardiovascular functions.[20] Furthermore, its mode of action
can easily be modified by small changes; e.g. an “A” ring
substitution (Scheme 1) or modification with a nitro group in
para position leads to aromatase inhibition (the enzyme
producing estrogen).[21]
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One further prominent example is the ferrocene-containing
derivative ferrocifen (Fc-diOH) (Scheme 1), which was reported
and extensively biologically tested by Jaouen et al.. Ferrocifen
showed redox chemistry useful for the generation of reactive
oxygen (ROS) and nitrogen species (RNS) via Fenton chemistry
induced by the ferrocene unit[22–24] and high activity towards
hormone-dependent (e.g. MCF-7) and “hormone-independent”
(e.g. MDA-MB-231) cell lines.[25] Also a few other metal complex-
based SERMs are known.[26] Even though estrogenic activity
(agonist or antagonist) was proven for ferrocifen, this effect is only
dominant at nanomolar concentrations, whereby other modes of
action, like induction of senescence (ca. 10  7 m), apoptosis (ca.
10  6–10  5 m) or Fenton chemistry (ca. 10  5–10  4 m) become the
predominant effects at higher concentrations of ferrocifen
in vitro.[27] However, so far, no metallacarborane was combined
with the tamoxifen lead structure. Therefore, the “A” ring in 1,1-bis
(4-hydroxyphenyl)-2-phenylbut-1-ene (TAM-diOH) was replaced
with a well-known chelating moiety (2,2’-bipyridine), being able to
coordinate a variety of potential biologically active transition
metals (be it a pharmacophore or a traceable element, etc.), with
the goal to obtain novel potential SERMs (Scheme 1).
We here report on the combination of this novel 2,2’-bpy-
TAM-diOH vector system with half-sandwich molybda-
carboranes.[28] For antitumor studies, a formulation strategy using
bovine serum albumin (BSA) that was developed by us was
applied, which led to a substantial increase in the biological
activity against the MCF-7 breast cancer cell line for the new
pharmacophore [3-(2,2’-bipyridine-k2N,N’)-3-(CO)2-closo-3,1,2-
MoC2B9H11] (i).[29]
Results and Discussion
Syntheses and Characterization
The synthesis of the 2,2’-bipyridine-substituted tamoxifen
derivative 6 (Scheme 2) via the facile McMurry coupling was not
successful, probably due to the electron-poor 2,2’-bipyridine
unit, which renders the ketone in compound 3 less reactive in
this type of olefination reaction, unlike the electron-rich
ferrocene derivative in the synthesis of ferrocifen.[30] Equally
unsuccessful was the use of 3 in a Wittig-Horner-type reaction.
Therefore, ligand 6 was constructed stepwise starting from the
commercially available 2-halo-isonicotinic acid (1a,b), which
was reduced to 1-(2-halopyridin-4-yl)propan-1-one (2a,b) with
ethylmagnesium bromide in tetrahydrofuran (THF) at   40 °C
(Scheme 2).[31] A [Pd(PPh3)4]-catalyzed Stille coupling reaction
resulted in the asymmetric 2,2’-bipyridine derivative (3) in
moderate to good yields (gram scale 56%, small scale 69%). A
Horner-Wadsworth-Emmons modification for the Ramirez gem-
dibromoolefination gave compound 4 in good yield (78%).[32] A
[Pd(PPh3)4]-catalyzed Suzuki coupling afforded compound 5 in
good yield (76%). Demethylation of the aryl-methyl ether 5
with BBr3 resulted in the final ligand 6.
[33] The conditions for the
optimization of both Pd0-catalyzed coupling reactions are given
in the Supporting Information (Tables S1 and S2, SI). Com-
pounds 3–6 were fully characterized by NMR, infrared spectro-
scopy, mass spectrometry, and elemental analysis; the solid-
state molecular structure of 6 was also confirmed by single
crystal X-ray diffraction methods (Figure S1, SI). After obtaining
the new ligands, coordination studies were performed with
[NEt4][3-(η
3-C3H5)-3-(CO)2-closo-3,1,2-MoC2B9H11] (7).
In 7, the acid-labile allyl ligand at molybdenum(II) was
released upon protonation and then replaced with the
respective N,N-chelating ligand 3, 5 and 6 to give the
molybdacarborane complexes 8, 9 and 10, respectively, accord-
ing to Schwarze et al. (Scheme 3).[28] Unlike the molybdacarbor-
anes bearing a simple 2,2’-bipyridine or 1,10-phenanthroline
ligand,[28] complexes 8–10 could be purified by flash column
chromatography on silica gel in low to moderate yields (18–
35%). These low yields are most likely related to a side reaction
Scheme 1. Bioisosteric replacement approach: from TAM-diOH to ferrocifen
(Fc-diOH), an aromatase inhibitor,[21] 2,2’-bpy-TAM-diOR (R=Me (5), H (6)),
[[3,3-{4-[1,1-bis(4-methoxyphenyl)but-1-en-2-yl]-2,2‘-bipyridine-k2N,N’}-3-
(CO)2-closo-3,1,2-MoC2B9H11] (9) or [3,3-{4-[1,1-bis(4-hydroxyphenyl)but-1-en-
2-yl]-2,2‘-bipyridine-k2N,N’}-3-(CO)2-closo-3,1,2-MoC2B9H11] (10).
Scheme 2. Synthetic route yielding the organic vector incorporating the
chelating 2,2‘-bipyridine unit. (a) EtMgBr (2.2 equiv.) in THF,   40 °C, 4 h; (b)
reflux conditions: 2-(tributylstannyl)pyridine (1.1 equiv.), [Pd(PPh3)4]
(10 mol%), CsF (2.2 equiv.), CuI (16 mol%) in DMF, 120 °C, 3 d; (c) microwave
conditions: 2-(tributylstannyl)pyridine (1.1 equiv.), [Pd(PPh3)4] (10 mol%), CsF
(2.2 equiv.), CuI (16 mol%) in DMF, 140 °C, 16 h; (d) CBr4, P(OiPr)3 in DCM, 0 °C
to 40 °C, 4 d; (e) CCl4, PPh3 in toluene, 110 °C, 3 d; (f) 4-methoxyphenylbor-
onic acid (5.0 equiv.), [Pd(PPh3)4] (10 mol%), Na2CO3 (5.0 equiv.) in 1,4-
dioxane/H2O (4 :1), 100 °C, 4 d; (g) BBr3 in DCM,   60 °C to rt, 12 h.
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which was not observed for the simple N,N-chelating ligands
(e.g. 2,2’-bipyridine or 1,10-phenanthroline).[28] During the
purification process, more than one violet band could be
observed for every complexation reaction. Exemplarily for 9, the
second violet fraction was collected in sufficient purity and
identified by 1H, 13C{1H}, 11B{1H} and 11B NMR spectroscopy, HR-
ESI mass spectrometry and diffraction methods as a chlorine
B(8)-substituted derivative of 9 (see SI), where the respective
position in the carborane ligand was activated for EINS-type
(electrophile induced nucleophilic substitution) reactions (9b,
Figure S2, SI).[34] This one-pot two-step reaction (proton-medi-
ated ligand exchange and EINS-type reaction at the dicarbol-
lide) was attempted before without success for complexes with
the 2,2’-bipyridine and 1,10-phenanthroline ligand, [3-(L-k2N,N’)-
3-(CO)2-closo-3,1,2-MoC2B9H11], with L=2,2’-bipyridine or 1,10-
phenanthroline, using different strong acids and solvents.[28]
Further studies for employing the chloride in carborane
substitution chemistry are in progress.
The color of all the ligands ranges from colorless to pale
yellow. On coordination to molybdenum(II), a color change to
deep purple is observed for complexes 8–10 (for UV-Vis spectra
of 6 and 10 see Figure S16, SI) indicating metal-to-ligand
(MLCT) and ligand-to-metal charge transfer (LMCT) (with L=3,
5 or 6).[28] In the infrared spectra, typical vibrations of all
functional groups are observed, e.g. ν(BH) (2595–2480 cm  1)
and ν(CO) (1955–1874 cm  1) vibrations, which are unique in
biological systems and could, therefore, be used for label-free
imaging (first attempts have been reported for [3-(2,2’-bipyr-
idine-k2N,N’)-3-(CO)2-closo-3,1,2-MoC2B9H11].
[29] In the 1H NMR
spectra of the complexes 8, 9 and 10, there is a clear
coordination shift observed compared to the chemical shifts of
the ligands 3, 5 and 6 (Figure S3–S5, SI). The CHcluster signals split
into two broad singlets due to the asymmetric N,N-chelating
ligand. Importantly, the coordination of 3, 5 and 6 at
molybdenum(II) always generates two isomers, which cannot
be distinguished via NMR spectroscopy. The carbonyl groups
are observed as two slightly different signals at 255.3 and
254.5 ppm (8, CD2Cl2), 256.3 and 255.5 ppm (9, CDCl3) or 260.3
and 260.0 ppm (10, CD3CN) in the
13C{1H} NMR spectra of the
respective complexes according to the C1 symmetry of the
whole molecule.
Obtaining HR-ESI mass spectra of molybdacarboranes is
challenging, since they cannot be ionized easily and are either
detectable in negative or positive mode. Additionally, a strong
clustering effect can be observed for complexes 8–10. For
illustration, one typical high-resolution ESI mass spectrum in
the negative mode is depicted in the supporting information
(Figure S18, SI), showing an agglomeration pattern, where the
unidentifiable agglomerate X (m/z=1965.6786) loses five times
a fragment [M  2H]2  . This effect can be minimized through
dissolution of the sample immediately before injection into the
ESI-MS instrument. This is a nice demonstration of the potential
agglomeration properties of metallacarboranes in solution.
Bioanalytical Measurements
For in vitro cell culture tests, the stock solutions of sparingly
water-soluble compounds are typically prepared in DMSO
(ethanol or methanol are good alternatives) and stored below
+4 °C. For that purpose, the chemical stability of 3, 5, 6 and 8–
10 was tested in a solution of water-containing DMSO-d6 in air
for at least 36 days (3, 5, 6, 8, 9) and for 14 days for complex 10.
1H and 11B{1H} NMR spectra revealed that the ligands 3, 5 and 6
can be stored in a DMSO stock solution for at least one month
without decomposition, and the molybdacarboranes for
14 days up to one month with minor decomposition (where the
decomposition products are the free ligands 3, 5 or 6, the nido-
carborane ([nido-C2B9H12]
  ) and most likely a molybdenum
species in higher oxidation states) (see Figure S6–S14). Recently,
we introduced a formulation procedure for sparingly water-
soluble metallacarboranes, using fatty acids- and magnesium-
free bovine serum albumin (BSAnoMg) in a 1 :10 molar ratio,
which led to a significant improvement of the reproducibility,
but also the cytotoxicity against MCF-7 breast cancer cells.[29]
Here, the biological activity of molybdacarboranes (8–10), as
well as ligands 3, 5 and 6, and literature-known reference
compounds (TAM-diOH and Fc-diOH) was evaluated employing
this formulation procedure to ensure comparability.
To understand the self-assembling behavior of metallacar-
boranes/BSAnoMg co-assemblies, exemplarily ligand 6 and com-
plex 10 were investigated in phosphate-buffered saline (PBS)/
DMSO mixtures at physiological pH (pH 7.4) by UV-Vis,
fluorescence and Rayleigh light scattering (RLS) spectroscopy,
as well as Nanoparticle Tracking Analysis (NTA).[9,29,35]
For the fluorescence spectra, three excitation wavelengths
were chosen (λexc=280, 295 and 320 nm) and the investigations
were performed with two site markers, namely warfarin and
ibuprofen, binding selectively to Sudlow’s site I or Sudlow’s site
II, respectively. The same systems were investigated by UV-Vis
spectroscopy in parallel. Our measurements revealed that 6
binds to both, Sudlow’s site I and II (Figure S15, SI).
Remarkably, the fluorescence intensity at λexc=280 nm is
quenched to the same extent when 6 only is mixed with
Scheme 3. Synthesis of the molybdacarboranes 8, 9 and 10 via protonation
of [NEt4][3-(η
3-C3H5)-3-(CO)2-closo-3,1,2-MoC2B9H11] (7) and reaction with N,N-
chelating ligands 3, 5 or 6. Both coordination isomers are formed for 8, 9
and 10.
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BSAnoMg or together with ibuprofen, indicating that the binding
strength is in the same order of magnitude as for the site
marker. The situation is slightly different for 10, which binds to
Sudlow’s site II, but the fluorescence is quenched more in the
ternary system together with BSAnoMg and ibuprofen. The
fluorescence intensity is quenched more when 10 is added first,
and ibuprofen afterwards, which might imply a weak coopera-
tive effect upon binding of both components (Figure S15, SI).
Evidently, there is a strong cooperative effect of both 6 and 10
with warfarin (at the excitation wavelengths λexc=295 and
320 nm), which is independent from the order of addition. Also,
tamoxifen acts differently, having a negative allosteric effect on
warfarin–HSA binding.[36] These findings are in contrast with the
ones for the molybdacarborane [3-(2,2’-bipyridine-k2N,N’)-3-
(CO)2-closo-3,1,2-MoC2B9H11] (i), which seems to bind stronger to
Sudlow’s site I than to site II, without any interaction being
detected between warfarin and i.[29] The absorption spectra of
the ternary systems (BSA-site marker-drug, Figure S16, SI) show
the same overall trend concerning binding events as the
fluorescence spectra. Notably, the UV-Vis spectrum of 10 in
PBS/DMSO mixture is essentially the same as for i; therefore,
similar electronic structures can be assumed.[28] The absorption
spectrum suggests that the solubility of 6 is improved on
binding to BSAnoMg, because the baseline shift, due to scattering,
is suppressed. This was confirmed by measuring Rayleigh Light
Scattering (RLS), which showed a decrease of scattering
aggregates, in an analogous way as we recently reported
(Figure S17 left, SI).[29] For 10, the binding to BSA (1 :1) seems to
increase the scattering according to RLS (Figure S17 right, SI).
Nanoparticle Tracking Analysis (NTA) measurements were
performed in a PBS/DMSO mixture exemplarily for 6 and 10,
with and without the addition of fatty acids- and magnesium-
free bovine serum albumin (BSAnoMg) in a 10 :1 ratio. A sharp
increase in particle concentration is observed when the
formulation protocol is applied for molybdacarborane 10 with
bimodal distribution (after deconvolution) and relatively low
polydispersity (Figure 1, right) being stable over 20 h, support-
ing the findings from previous studies.[29] Interestingly, when
the aggregation behavior of only the ligand 6 is investigated,
no such effect is observed. Indeed, the very broad size
distribution of particles of 6 in PBS/DMSO is transformed into a
size distribution that resembles BSA in PBS/DMSO (Figure 1,
left) implying that 6 is bound to BSA (see also spectroscopic
data: Figure S15–S16, SI), but does not induce agglomeration as
metallacarboranes do. Thus, these findings are a strong
evidence that metallacarboranes form nano-sized aggregates
with BSAnoMg, which cannot be observed for organic hormone-
like structures, even though binding to BSAnoMg was proven for
6 via UV-Vis and fluorescence spectroscopy.
In vitro Cell Colorimetric Assays
After we found evidence of cytotoxic activity of [3-(2,2’-
bipyridine-k2N,N’)-3-(CO)2-closo-3,1,2-MoC2B9H11] (i) against
MCF-7 cells,[29] we wanted to expand our studies to other
molybdacarboranes with N,N-chelating ligands and a larger
panel of cell lines, i. e. three breast cancer adenocarcinomas
(MDA-MB-231, MDA-MB-361 and MCF-7), human glioblastoma
(LN-229) and human glioma (U-251) cell lines, plus mouse
macrophages (Mf), as an example for non-malignant immune
cells (Table 1 and Figures S19 and S20, SI). Cells were exposed
to 3, 6 and 8–10 for 72 h, after which 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) and crystal violet
(CV) cell viability assays were performed.
As we found an improvement of the cytotoxicity for i upon
formulation with BSAnoMg in a 1 :10 ratio (compound:BSAnoMg) in
previous studies, we performed all studies presented here with
the mentioned formulation protocol, also for the non-metal-
lacarborane compounds 3 and 6, as well as the two reference
compounds 1,1-bis(4-hydroxyphenyl)-2-phenylbut-1-ene (TAM-
diOH) and ferrocifen (Fc-diOH). Under the applied conditions of
Figure 1. Size distribution of 6 (left) and 10 (right) in PBS/DMSO mixtures from NTA measurements. Ratio BSAnoMg:6 or 10 was 10 :1. [6]= [10]=20 μm, [BSA]
=200 μm. The dilution factors are adjusted to 11x for each sample. Samples were measured 1.5–22.25 h after preparation. The respective blanks (BSAnoMg in
PBS/DMSO) are measured after 2.2 h (6) or 2.4 h (10); 6 in PBS/DMSO after 2 h, 10 in PBS/DMSO after 0.5 h. Standard deviation (SD) for particle concentration
is �1.30–3.68×106 (samples regarding 6) and �2.68×106–3.88×107 (samples regarding 10) particles mL  1, for particle size �4–18 nm.
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the biological evaluation, 5 was not suitable for testing due to
precipitation from the solution, and 9b could not be obtained
in sufficient purity. The results revealed that ligand 3 and the
corresponding metallacarborane 8 have moderate to low
cytotoxic activity on the studied cell lines. In all cases, except
for the MCF-7 cells, the IC50 values for molybdacarborane
complexes are slightly higher than for the respective ligands
alone. Complex 9, bearing a vector which is closer to the lead
structure of TAM-diOH, performs expectedly better, especially
against the MCF-7 cell line (Table 1). Remarkably, also the
human glioblastoma cells (LN-229) and human glioma cells (U-
251) were sensitive towards treatment with 9 in the low/
moderate micromolar range. The couple 6 and 10 showed
activity against all tested cell lines in the low micromolar range
(Table 1). Worth highlighting is that the substitution of the
phenyl ring “A” in TAM-diOH by a chelating 2,2’-bipyridine unit
does not only improve the anticancer activity for all tested
breast cancer cell lines, but also provides cytotoxic activity
against the very aggressive primary malignant glioblastoma
cells (LN-229) and the invasive, malignant human glioma cells
(U-251). The anticancer activity for Fc-diOH could be repro-
duced also with the BSAnoMg formulation protocol.
[37] In general,
the IC50 values for Fc-diOH against all malignant cell lines are
lower than for the other tested compounds; however, 6, 9 and
10 come close to the same activity range, depending on the
cell line. Remarkably, the absolute toxicity of Fc-diOH against
healthy immune cells (mouse macrophages, Mf) is considerably
high (20.6�0.6 μm) compared to 3, 6 and 8–10 (>100 μm)
(Table 1 and Figure S20, SI). This issue has already been
reported for ferrocifen-type anticancer drugs, showing an
analogous high absolute toxicity (10 μm) against healthy brain
tissue in vivo.[38] However, relatively seen the preferential
selectivity towards tumor cells is generally higher for Fc-diOH
(considering the experimental cut-off at 100 μm). This, however,
does not extend to 6 regarding all breast cancer cell lines and
for 10 in the cases of the MDA-MB-361 and MCF-7 cell lines.
Western blot analysis was performed to assess the estrogen
receptor status (see Figure S21, SI), However, it seems that the
anticancer potential of our newly designed compounds is not
in correlation with estrogen receptor expression, under the
applied concentrations, indicating the existence of other targets
for these molecules.
Flow Cytometry
To evaluate a possible mode of action of the new compounds,
6 and 10 were selected for further analysis on the MCF-7 cell
line by flow cytometry. Fc-diOH was also tested, as reference,
for comparison. All following investigations were performed
applying the BSAnoMg formulation protocol.
Both 6 and 10 showed the same moderate inhibitory
properties on cell proliferation (carboxyfluorescein succinimidyl
ester (CFSE) staining, Figure 2A), whereas Fc-diOH featured
stronger inhibition of the proliferation, in line with the literature
for all ferrocifen-type anticancer drugs.[27] Senescence-associ-
ated (SA) β-galactosidase staining revealed that 6 induces
senescence to a minor extent compared to the transition metal-
containing 10 and ferrocifen (Figure 2B).[39]
Cellular senescence is an important mechanism to prevent
tumor cell proliferation and might result in cellular death.[40]
However, the detailed role of senescence in general was found to
be way more complicated, because this process not only arrests
the cell cycle, but it also stimulates the cells to produce numerous
growth factors and other proteins (also called senescence-
associated secretory phenotype, SASP), which can, in turn, provoke
again tumor promotion but also tissue repair.[41] Annexin-V/PI
double staining indicates that apoptosis is not the main mode of
action for either 6 or 10 (Figure 2C), which is the case for the
reference compounds and for ruthenacarboranes.[8,27,42]
These results could be supported by 4’,6-diamidino-2-
phenylindole (DAPI) staining, highlighting shrunken nuclei with
condensed chromatin as sign of apoptosis (Figure 2D, red
Table 1. IC50 values for 3, 6, 8–10 from MTT and CV cell viability assays. Standard deviations for each IC50 value are given.
IC50 [μm]
Cells
Compound Assay MDA-MB-231 MDA-MB-361 MCF-7 U-251 LN-229 Mf
3 MTT 42.0�3.4 78.1�3.8 43.0�2.9 38.0�3.0 47.2�0.9 –[a]
CV 38.1�3.5 70.5�5.2 41.3�2.2 44.1�1.6 54.9�4.1 >100
6 MTT 2.2�0.2 2.4�0.2 1.8�0.4 15.2�0.6 15.8�2.0 –[a]
CV 2.5�0.2 2.8�0.3 2.1�0.6 21.0�3.5 17.7�1.0 >100
8 MTT >100 71.0�4.4 34.4�1.7 97.4�3.7 >100 –[a]
CV >100 75.7�5.0 27.9�3.5 55.8�5.1 >100 >100
9 MTT 38.2�1.4 18.3�1.4 6.0�0.6 17.2�0.6 21.9�1.6 –[a]
CV 30.8�2.8 18.1�2.4 6.6�0.9 17.4�1.0 25.8�1.7 >100
10 MTT 17.8�2.0 4.0�0.4 9.3�0.5 30.1�2.8 38.0�0.9 –[a]
CV 18.5�1.1 4.5�0.6 5.0�0.7 32.7�3.8 41.0�3.8 >100
TAM-diOH MTT 15.4�0.6 24.5�3.6 24.3�1.6 >100 >100 –[a]
CV 16.8�1.3 33.9�1.3 25.3�2.4 >100 >100 97.1�4.2
Fc-diOH MTT 1.0�0.1 1.5�0.3 1.0�0.1 1.4�0.2 3.1�0.2 –[a]
CV 0.9�0.1 2.3�0.2 1.0�0.1 1.7�0.1 2.6�0.3 20.6�0.6
All experiments were done using BSAnoMg formulation strategy (BSA/small molecule (10 :1)), before dilution with cell culture medium. Cell viability is
expressed as percentage (%) relative to control and presented as mean � SD of three independent experiments performed in triplicate. [a] “–“ means not
tested. Only minor discrepancies in the calculated IC50 values obtained from the two assays (MTT or CV) were found for most of the tested compounds.
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arrows), in the case of 10 to a lesser extent than for Fc-diOH.
However, for 6 a prevalent observation is the presence of
irregular-shaped shrunken nuclei (Figure 2D, yellow arrows)
indicating sporadic cells with apoptotic morphology. In con-
cordance with the data above, the activation of caspases was
only detected upon treatment of MCF-7 cells with Fc-diOH
(Figure 2E).
Additionally, autophagy processes were triggered by all
three tested compounds (Figure 3A); however, different modes
of action could be detected after treatment with the autophagy
inhibitor 3-methyladenine (3-MA). Since Fc-diOH further lowers
the cell viability when applied in combination with 3-MA, the
autophagy process can be considered as cytoprotective (pro-
survival) (Figure 3A, bottom right panel), while the addition of 6
as well as 10 together with 3-MA resulted in restored viability
compared to 6 (or 10) alone, and it can therefore be regarded
as cytodestructive (cell death mediating, Figure 3A, upper right
and bottom left panel). This non-apoptotic and autophagy-
mediated cell death mechanism could be the pathway of how 6
and 10 act on the tested cancer cells. In the literature, also
autophagy is discussed as a double-edged sword, depending
on healthy or cancer cell type, microenvironment, and develop-
ment status.[43]
Figure 2. Flow cytometry analysis of MCF-7 cells exposed (72 h) to an IC50 dose of 6, 10 or Fc-diOH, respectively, applying the BSAnoMg formulation procedure.
(A) CFSE staining, fluorescence intensity from the FL1 channel (green emission); (B) senescence-associated (SA) β-galactosidase staining, fluorescence intensity
from the FL1 channel; (C) AnnV/PI double staining, fluorescence intensity from FL2 (y axis, orange emission) vs. FL1 (x axis) channel; (D) DAPI-stained cells
observed under a fluorescence microscope (magnification x200), red arrows indicate shrunken nuclei with condensed chromatin, yellow arrows indicate
irregular shape of nuclei as morphologic signs of apoptosis; (E) ApoStat staining for caspase-dependent apoptosis, fluorescence intensity from the FL1
channel. Experiments were run in triplicate. The representations are based exemplarily on one experiment. For each staining protocol, the respective control
(cells treated with BSAnoMg) is also shown.
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While in the luminal breast cancer cell line MCF-7 autophagy
seems to be a reasonable cell death process, it was recently shown
for other common chemotherapeutics that autophagy in e.g.
MDA-MB-231 cells is dependent on other signaling pathways.[44]
Autophagy, as one of the main cellular processes, can have a large
spectrum of physiological functions affecting cell fate in various
ways. Its specific role, however, is determined by the cell
specificity, the intensity of triggered processes, as well as the type
of the chemotherapeutic that induced it.[45]
To investigate the capability of the drugs to generate
reactive oxygen/nitrogen species (ROS/RNS), dihydrorhodamine
123 (DHR 123) staining was performed. It could be shown for
Fc-diOH that the ROS/RNS levels in the treated cells were
increased, as it is reported in the literature via the inhibition of
cytoprotective radical scavenger thioredoxin,[46] as well as the
self-generation of ROS/RNS species, which all together lead to
apoptosis also in hormone-independent cell lines.[22] Similarly,
other ferrocene-containing bioactive molecules induce apopto-
sis through the generation of ROS.[23,47] In contrast, both 6 and
10 “scavenge” or lower the cellular ROS/RNS levels (DHR 123,
dihydrorhodamine 123 staining; Figure 3C), which corresponds
well with the absence of caspase-dependent apoptosis induc-
tion. Worth mentioning is that the molybdacarborane 10 is way
more efficient in scavenging/reducing radical concentration
compared to its ligand (6) only. How exactly 6 and 10 lower the
cellular ROS/RNS levels remains unclear and will be addressed
in future studies.
Remarkably, compound 10 strongly upregulates the NO
production in MCF-7 cells (Figure 3B). Either it scavenges ROS/
RNS and thus generates NO, or it interacts with one or more of
the nitric oxide synthases (NOS), as known for other mixed-
sandwich ferracarborane or COSAN-type structures.[7] This effect
Figure 3. Flow cytometry analysis of MCF-7 cells exposed (72 h) to an IC50 dose of 6, 10 or Fc-diOH, respectively, applying the BSAnoMg formulation procedure.
(A) AO staining (upper left panel), fluorescence intensity from the FL3 channel (dark red emission) for detection of acidic vacuoles; cell viability of MCF-7 cells
was determined via CV assays upon treatment with 3-MA, 6, 10 or Fc-diOH and 3-MA with 6, 10 or Fc-diOH. Experiments were run in triplicate. The respective
control (cells treated with BSAnoMg) is also shown. p<0.05 in comparison to * non-treated cells or # treated with the respective compounds alone (6, 10 or Fc-
diOH). (B) DAF-FM (4-amino-5-methylamino-2’,7’-difluorofluorescein) staining allows to detect the nitric oxide (NO) level, fluorescence intensity from the FL1
channel; (C) DHR 123 staining for determination of the ROS/RNS species, fluorescence intensity from the FL1 channel (green emission). For flow cytometry,
experiments were run in triplicate. The representations are based exemplarily on one experiment. For each staining protocol, the respective control (cells
treated with BSAnoMg) is also shown.
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is in high contrast to the other two tested compounds (6 and
Fc-diOH) in flow cytometry analysis. Also, nitric oxide has an
ambivalent role in healthy and cancer cell correlation.[48] In low
concentrations, i. e. 10   300 nm, proliferation of MCF-7 cells
could be induced via HIF-1α (hypoxia-induced factor 1α),
whereas in higher concentrations, i. e. >300 nm, the p53 tumor
protein is further phosphorylated inducing an apoptotic cell
death mechanism.[49]
Conclusions
We could synthesize a 2,2’-bipyridine vector (6) in five synthetic
steps that can be employed as ligand for a large variety of
organometallic or inorganic transition metal complex fragments
giving distinct functions to the whole complex. The activity of
the prototypic molybdacarborane [3-(2,2’-bipyridine-k2N,N’)-3-
(CO)2-closo-3,1,2-MoC2B9H11] (i), already active against MCF-7
breast cancer cell line (IC50=ca. 40 μm),
[29] could be improved
by incorporating the 2,2’-bpy-TAM-diOH (6) ligand. Further-
more, the ligands 3 and 6 were tested in cell viability studies
(CV and MTT assays) in comparison to the respective molybda-
carborane complexes (8–10) against breast adenocarcinoma
(MDA-MB-231, MDA-MB-361 and MCF-7), human glioblastoma
(LN-229) and human glioma (U-251) cell lines and showed IC50
values in low to moderate micromolar range. Importantly,
viability of mouse macrophages (Mf) was not significantly
affected by the new compounds up to a concentration of
100 μm, in contrast to Fc-diOH. Modification of the “A” ring in
4,4’-dihydroxytamoxifen (TAM-diOH) or ferrocifen (Fc-diOH)
with 2,2’-bipyridine or [3-(2,2’-bipyridine-k2N,N’)-3-(CO)2-closo-
3,1,2-MoC2B9H11] modulates the anticancer activity profile
significantly. Compounds 6 and 10 were found to have
distinctly diverse activities (compared to Fc-diOH), e.g. induc-
tion of senescence, cytodestructive autophagy, lowering of
ROS/RNS levels, and, uniquely for 10, strong increase of nitric
oxide (NO) concentration. In perspective, it might be a good
chance that the tested compounds are active on different
routes rather than causing apoptosis, because most anticancer
drugs kill through apoptotic cell death, thus having only little
effect on cancer cell lines with defects in the classical apoptotic
signaling pathway.[50] Further details on the mode of action of 6
and 10 are under way.
This study shows that half-sandwich molybdacarboranes are
highly interesting bioactive pharmacophores with distinct
activity profile, which can modulate the mode of action of
established organic and organometallic anticancer agents.
Additionally, it could be shown via Nanoparticle Tracking
Analysis (NTA) that the metallacarborane unit is essential for
triggering the formation of nanoparticles upon preparation
with bovine serum albumin (BSAnoMg), which might have a
positive impact on in vivo studies. Thus, both, 6 and 10, are
promising drug candidates for application in breast cancer,
glioma and glioblastoma therapy.
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activity profile contrasts with those
of other organic or inorganic
selective estrogen receptor modula-
tors: whereas the ROS/RNS levels are
decreased, the NO levels increase.
The ability to form nanoparticles
with bovine serum albumin opens
the way to modern nanomedicine.
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2,2’-Bipyridine-Modified Tamoxifen:
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